IntelGenx Faces FDA Hurdle for Pain Management Drug
Company Announcements

IntelGenx Faces FDA Hurdle for Pain Management Drug

IntelGenx Technologies (IGXT) has released an update.

IntelGenx Corp. has announced that their partner, Xiromed LLC, received a Complete Response Letter from the FDA for the ANDA of Buprenorphine Buccal Film, a generic version of the pain management opioid Belbuca. The FDA has requested additional Pharmaceutical Quality information but confirmed no new inspections are needed at IntelGenx’s facility. The company’s CEO expressed commitment to addressing the FDA’s feedback promptly.

For further insights into IGXT stock, check out TipRanks’ Stock Analysis page.

Related Articles
TipRanks Auto-Generated NewsdeskIntelGenx Restructures and Leadership Overhaul Approved
TheFlyIntelGenx granted court approcal of sale proposal from Atai Life Sciences
TipRanks Canadian Auto-Generated NewsdeskIntelGenx Shows Promise in Alzheimer’s Study
Looking for investment ideas? Subscribe to our Smart Investor newsletter for weekly expert stock picks!
Get real-time notifications on news & analysis, curated for your stock watchlist. Download the TipRanks app today! Get the App